Atomic AI develops RNA-targeted therapeutics using machine learning combined with structural biology, focused on discovering RNA-centric medicines that span both small molecules targeting RNA and RNA-based drugs themselves.
The company’s proprietary ATOM-1 foundation model provides what it describes as the world’s most precise predictions of RNA structure and function, enabling therapeutic approaches that weren’t previously feasible. The R&D platform integrates ATOM-1 with custom wet-lab assays in an iterative cycle, pairing computational prediction with physical experimental validation to accelerate drug development rather than relying on either alone.
Atomic AI targets pharmaceutical and biotech organizations pursuing RNA-based drug development. The company’s research has been published in Science Magazine, offering peer-reviewed validation of the approach; pricing isn’t applicable in the traditional sense, as this is a research and drug-development platform rather than a subscription product.
